Fig. 1

CEBPD is highly expressed in PTX-resistant TNBC cells. A volcano plots for DEGs identified using GSE28784 and GSE90564 datasets; B intersections between the two sets of DEGs and human transcription factors; C correlations between CEBPD and HEY1 (HESR-1) and OS of breast cancer analyzed by Kaplan–Meier Plotter analysis; D expression of CEBPD in biopsy tissues of SD/PD (n = 18) and CR/PR (n = 23) patients measured by IHC assay; E viability of parental (MDA-MB-231, MDA-MB-468, and MDA-MB-453) and PTX-resistant (MDA-MB-231/PTX, MDA-MB-468/PTX, and MDA-MB-453/PTX) cells and the PTX IC50 examined by CCK-8 assay (n = 3). Parental and PTX-resistant TNBC cells were treated with a fixed dose of 15 nM for 48 h for subsequent use. F colony formation ability of parental and PTX-resistant TNBC cells after PTX treatment (n = 3); G apoptosis of parental and PTX-resistant TNBC cells after PTX treatment determined by flow cytometry (n = 3); H migration and invasion of parental and PTX-resistant TNBC cells after PTX treatment determined by flow cytometry (n = 3); I CEBPD expression in parental and PTX-resistant TNBC cells measured by WB analysis (n = 3). Differences were analyzed by the t-test (D) or one-way ANOVA with Tukey's post-hoc test (F-I). IC50 of PTX in cells was analyzed by nonlinear fitting analysis (E). *p < 0.05